BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

ACT-Accelerator strategy calls for $23.4 B investment for global access to COVID-19 solutions

October 29, 2021 | News

Inequitable access to COVID-19 tests, treatments and vaccines is prolonging the pandemic everywhere and risking the emergence of new, more dangerous variants



The Access to COVID-19 Tools (ACT) Accelerator has launched its strategic plan and budget for the next 12 months, outlining the urgent actions and funding needed to address deep inequities in the COVID-19 response, save millions of lives and end the acute phase of the pandemic.

The ACT Accelerator strategic plan sets out urgent actions to address crucial gaps in access to COVID-19 tests, treatments, vaccines and personal protective equipment in low- and middle-income countries, using the latest epidemiological, supply and market information.

Delivering this plan is crucial to reaching globally agreed targets for COVID-19 tools, to help prevent at least 5 million potential additional deaths, save the global economy more than $5.3 trillion, and accelerate the end of the pandemic everywhere.

The ACT-Accelerator needs $23.4 billion until September 2022 to implement this plan, reflecting a fresh scope, advances in science and supply, and new actors joining the pandemic response.

The new plan also responds to the recent independent Strategic Review's key recommendations and will be implemented alongside global health, government, civil society and private sector partners.